View of Assessing the clinical impact of sodium-glucose cotransporter type 2 (SGLT2)- inhibitors in treating heart failure with reduced ejection fraction

Return to Article Details Assessing the clinical impact of sodium-glucose cotransporter type 2 (SGLT2)- inhibitors in treating heart failure with reduced ejection fraction Download Download PDF